drugset / Trial / NCT00789165

Empiric Quinidine for Asymptomatic Brugada Syndrome

NCT00789165

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The purpose of this study is to determine if quinidine therapy (not guided by the results of electrophysiologic studies) will reduce the long-term risk of arrhythmic events in asymptomatic Brugada Syndrome.

Timeline

Start
2009-12
Primary completion
2020-02
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Quinidine Small molecule 600 mg
Subject Quinidine Small molecule 900 mg